Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats

Antiviral Chemistry and Chemotherapy

Volumn 13, Issue 1, 2002, Pages 17-26

  Gao, Weihua ^a   Kishida, Tomoyuki ^a   Kageyama, Michiharu ^a   Kimura, Keisuke ^a   Yoshikawa, Yukako ^a   Shibata, Nobuhito ^a   Takada, Kanji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Amprenavir; First pass effect; HIV protease inhibitor; Indinavir; Nelfinavir; Pharmacokinetic interaction; Saquinavir

Indexed keywords

AMPRENAVIR; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG METABOLISM; EXTRACELLULAR FLUID; FIRST PASS EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE ABSORPTION; LIVER MICROSOME; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0036462252     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020201300102     Document Type: Article

References (27)

1. Barry M, Gibbons S, Back D & Mulcahy F (1997) Protease inhibitors in patients with HIV disease. Clinical Pharmacokinetics 32:194-209.
2. Barry M, Mulcahy F, Merry C, Gibbons S & Back D (1999) Pharmacokinetics and potential interactions among antiretroviral agents used to treat patients with HIV infection. Clinical Pharmacokinetics 36:289-304.
3. Boxenbaum H (1980) Interspecies variation in liver weight, hepatic blood flow and antipyrine intrinsic clearance in extrapolation of data to benzodiazepines and phenytoin. Journal of Pharmacokinetics & Biopharmaceutics 8:165-176.
4. Caroline GL, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan R & Dey S (1998) HIV-1 protease inhibitors are substrates for MDR1 mutidrug transporter. Biochemistry 37:3594-3601.
5. Chiba M, Hensleigh M & Lin JH (1997) Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Biochemical Pharmacology 53:1187-1194.
6. Coo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR & Kim RB (2000) Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and tesis. Drug Metabolism & Disposition 28:655-660.
7. Finzi D, Blankson J & Siliciano DJ (1999) Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV, even in patients on effective combination therapy. Nature Medicine 5:512-519.
8. Gao W, Kishida T, Kimura K, Kegayama M, Sumi M, Yoshigawa Y, Shibata N & Takada K (2002) Sensitive and simultaneous determination of HIV protease inhibitors in rats biological samples by liquid chromatography-mass spectrometry. Biomedical Chromatography 16:267-273.
9. Hoetelmans RM, Reijers MH, Weverling GJ, ten Kate RW, Wit FW, Mulder JW, Weigel HM, Frissen PH, Roos M, Jurriaans S, Schuitemaker H, de Wolf F, Beijnen JH & Lange JMA (1998) The effect of plasma drug concentrations on HIV clearance rate during quadruple drug therapy. AIDS 12:F111-F115.
10. Houston JB (1994) Utility of in vitro drug metabolism data in prediction of in vivo metabolic clearance. Biochemical Pharmacology 47:1469-1479.
11. Hsu A, Granneman GR, Cao G, Carothers L, Japour A, El-Shourbagy T, Dennis S, Berg J, Erdoman K, Leonard JM & Sun E (1998) Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrobial Agents & Chemotherapy 42:2784-2791.
12. Jerome HH, Chiba M, Yamazaki M, Tang C & Lin JH (2001) P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4. Journal of Pharmacology & Experimental Therapeutics 298:323-330.
13. Kim EJ, Han KS & Lee MG (2000) Intestinal first-pass effect of bumetanide in rats. International Journal of Pharmaceutics 194:193-199.
14. Kim J, Kim EJ, Han KS, Chang MS & Lee MG (1999) Gastrointestinal first-pass effect of YJA-20379-8, a new reversible proton pump inhibitor, in rats. Journal of Pharmacy & Pharmacology 51:1031-1036.
15. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM & Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. Journal of Clinical Investigation 101:289-294.
16. Lin JH, Sugiyama Y, Awazu S & Hanano M (1982) Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. Journal of Pharmacokinetics and Biopharmaceutics 10:649-661.
17. Pang KS & Rowland M (1977) Hepatic clearance of drugs: 1. Theoretical consideration of a 'well-stired' model and a 'parallel tube' model. Influence of hepatic blood flow, plasma and blood cell binding clearance. Journal of Pharmacokinetics and Biopharmaceutics 5:625-653.
18. Sato H, Hidenori K, Isao A & Isamu H (1996) Microdialysis assessment of microfibrous collagen conaining a p-glycoprotein-mediated transport inhibitor, cyclosporine A, for local delivery of etoposide. Pharmacological Research 13:1565-1569.
19. Shibata N, Matsumura Y, Okamoto H, Kawaguchi Y, Ohtani A, Yoshikawa Y & Takada K (2000) Pharmacokinetic interaction between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors. Journal of Pharmacy & Pharmacology 52:1239-1246.
20. Shibata N, Gao W, Okamoto H, Kishida T, Yoshikawa Y & Takada K (2002). In vitro and in vivo pharmacokinetic interactions of Amprenavir, an HIV-1 protease inhibitor, with other current HIV-1 protease inhibitors in rats. Journal of Pharmacy & Pharmacology 54:221-229.
21. Shibata N, Gao W, Okamoto H, Kishida T, Yoshikawa Y & Takada K (2002) Drug interaction between HIV protease inhibitors based on physiological-based pharmacokinetics model. Journal of Pharmaceutical Science 91:680-689.
22. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD & Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clinical Pharmacology & Therapeutics 59:491-502.
23. Vanhove GF, Gries JM, Verotta D, Sheiner LB, Coombs R, Collier AC & Blaschke TF (1997) Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrobial Agents and Chemotherapy 41:2433-2488.
24. Von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelmmann SM, Daily JP, Harmatz JS & Shader RI (1998) Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. Journal of Clinical Pharmacology 38:106-111.
25. Williams GC & Sinko PJ (1999) Oral absorption of the HIV protease inhibitors: a current update. Advanced Drug Delivery Review 39:211-238.
26. Yamaji H, Matsumura Y, Yoshikawa Y & Takada K (1999) Pharmacokinetic interactions between HIV-protease inhibitors in rats. Biopharmaceutics & Drug Disposition 20:241-247.
27. Yoshikawa Y, Kato K, Sone H & Takada K (1998) Development and evaluation of noncompartmental pharmacokinetic analysis program 'WinHARMONY' using Visual BASIC language having a function of automatic recognition vs time profile. Japanese Journal of Clinical Pharmacology & Therapeutics 29:475-487.